Alex­ion's cash cow re­ceives la­bel ex­pan­sion; Matthew Dal­las tapped to CFO post at Zealand Phar­ma

→ Back in June, Alex­ion‘s cash cow Soliris scored an ad­di­tion­al FDA OK for the treat­ment of neu­romyelitis op­ti­ca spec­trum dis­or­der (NMOSD) — and to­day the drug was waved for a la­bel ex­pan­sion by the Eu­ro­pean Com­mis­sion (EC).

The EC based its ap­proval on re­sults from the Phase III ran­dom­ized, dou­ble-blind, place­bo-con­trolled PRE­VENT study and long-term ex­ten­sion study (ECU-NMO-302) — with the lat­ter still un­der­way. “The study met its pri­ma­ry end­point of pro­long­ing the time to first ad­ju­di­cat­ed re­lapse and re­duc­ing the risk of re­lapse. Per the da­ta, 98% of adult AQP4 an­ti­body-pos­i­tive pa­tients treat­ed with Soliris were re­lapse-free com­pared to 63% re­ceiv­ing place­bo at 48 weeks,” read a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER